ADNI 的起源。

IF 13 1区 医学 Q1 CLINICAL NEUROLOGY Alzheimer's & Dementia Pub Date : 2024-10-06 DOI:10.1002/alz.14256
William Z. Potter, Neil S. Buckholtz, Steven M. Paul
{"title":"ADNI 的起源。","authors":"William Z. Potter,&nbsp;Neil S. Buckholtz,&nbsp;Steven M. Paul","doi":"10.1002/alz.14256","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <p>A brief history of events surrounding the conceptualization and original implementation of the Alzheimer's Disease Neuroimaging Initiative (ADNI) as a public–private partnership (PPP) is provided from the perspective of three individuals directly involved from the outset. Potential barriers and how they were addressed are summarized, especially the decision to make all data freely accessible in real-time. Decisions made at the beginning of ADNI are revisited in light of what has been learned over the past 20 years, especially the importance of the investment in cerebrospinal fluid (CSF) and blood measures and the commitment to data sharing. The key elements of ADNI's success from the authors’ perspective are also summarized.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>Informal interactions among colleagues were the beginning of something big.</li>\n \n <li>An NIH Director's personal decision on open data sharing has had perhaps the greatest impact of any single decision in the past several decades in terms of advancing clinical biomarker research.</li>\n \n <li>After 20 years, blood-based biomarkers of brain disease may soon take the place of brain imaging for purposes of diagnosis and drug development.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"20 11","pages":"8188-8191"},"PeriodicalIF":13.0000,"publicationDate":"2024-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11567829/pdf/","citationCount":"0","resultStr":"{\"title\":\"The origins of ADNI\",\"authors\":\"William Z. Potter,&nbsp;Neil S. Buckholtz,&nbsp;Steven M. Paul\",\"doi\":\"10.1002/alz.14256\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <p>A brief history of events surrounding the conceptualization and original implementation of the Alzheimer's Disease Neuroimaging Initiative (ADNI) as a public–private partnership (PPP) is provided from the perspective of three individuals directly involved from the outset. Potential barriers and how they were addressed are summarized, especially the decision to make all data freely accessible in real-time. Decisions made at the beginning of ADNI are revisited in light of what has been learned over the past 20 years, especially the importance of the investment in cerebrospinal fluid (CSF) and blood measures and the commitment to data sharing. The key elements of ADNI's success from the authors’ perspective are also summarized.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Highlights</h3>\\n \\n <div>\\n <ul>\\n \\n <li>Informal interactions among colleagues were the beginning of something big.</li>\\n \\n <li>An NIH Director's personal decision on open data sharing has had perhaps the greatest impact of any single decision in the past several decades in terms of advancing clinical biomarker research.</li>\\n \\n <li>After 20 years, blood-based biomarkers of brain disease may soon take the place of brain imaging for purposes of diagnosis and drug development.</li>\\n </ul>\\n </div>\\n </section>\\n </div>\",\"PeriodicalId\":7471,\"journal\":{\"name\":\"Alzheimer's & Dementia\",\"volume\":\"20 11\",\"pages\":\"8188-8191\"},\"PeriodicalIF\":13.0000,\"publicationDate\":\"2024-10-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11567829/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alzheimer's & Dementia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/alz.14256\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/alz.14256","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

本文从从一开始就直接参与其中的三位人士的角度,简要介绍了阿尔茨海默病神经影像计划(ADNI)作为公私合作伙伴关系(PPP)的构思和最初实施的历史。文中总结了潜在的障碍以及如何解决这些障碍,尤其是免费实时访问所有数据的决定。根据过去 20 年的经验教训,重新审视了 ADNI 创立之初所做的决定,尤其是对脑脊液 (CSF) 和血液测量的投资以及对数据共享的承诺的重要性。作者还总结了 ADNI 成功的关键因素。亮点:同事之间的非正式互动是大事的开端。美国国立卫生研究院(NIH)院长关于开放数据共享的个人决定也许是过去几十年中对临床生物标记物研究产生最大影响的单一决定。20 年后,基于血液的脑疾病生物标志物可能很快就会取代脑成像技术,用于诊断和药物开发。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
The origins of ADNI

A brief history of events surrounding the conceptualization and original implementation of the Alzheimer's Disease Neuroimaging Initiative (ADNI) as a public–private partnership (PPP) is provided from the perspective of three individuals directly involved from the outset. Potential barriers and how they were addressed are summarized, especially the decision to make all data freely accessible in real-time. Decisions made at the beginning of ADNI are revisited in light of what has been learned over the past 20 years, especially the importance of the investment in cerebrospinal fluid (CSF) and blood measures and the commitment to data sharing. The key elements of ADNI's success from the authors’ perspective are also summarized.

Highlights

  • Informal interactions among colleagues were the beginning of something big.
  • An NIH Director's personal decision on open data sharing has had perhaps the greatest impact of any single decision in the past several decades in terms of advancing clinical biomarker research.
  • After 20 years, blood-based biomarkers of brain disease may soon take the place of brain imaging for purposes of diagnosis and drug development.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Alzheimer's & Dementia
Alzheimer's & Dementia 医学-临床神经学
CiteScore
14.50
自引率
5.00%
发文量
299
审稿时长
3 months
期刊介绍: Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.
期刊最新文献
Sex differences in the trajectories of plasma biomarkers, brain atrophy, and cognitive decline relative to amyloid onset Heritability of Alzheimer's disease plasma biomarkers: A nuclear twin family design Elevated locus coeruleus metabolism provides resilience against cognitive decline in preclinical Alzheimer's disease The Consortium for Clarity in ADRD Research Through Imaging (CLARiTI) Communication Bridge-2 randomized controlled trial: Recruitment and baseline features
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1